Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 623 (Blisibimod) in Systemic Lupus Erythematosus
NCT02411136Phase 1Completed
- Sponsor
- Amgen
- Start
- May 2005
- Primary completion
- Aug 2007
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing AMG 623 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events up to 31 weeks, Incidence of abnormal clinically significant vital signs up to 31 weeks and 2 more. Started May 2005; status: completed.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02411136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411136.